Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation - NICE TAG TA429

1.1 Ibrutinib alone is recommended within its marketing authorisation as an option for treating chronic lymphocytic leukaemia in adults:

who have had at least 1 prior therapy or
who have a 17p deletion or TP53 mutation, and in whom chemo-immunotherapy is unsuitable and
only when the company provides ibrutinib with the discount agreed in the patient access scheme.